Industry Briefs: December 10, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: December 10, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Amorfix Life Sciences has established a collaboration with CNJ Holdings, a wholly owned subsidiary of Cangene, for the identification and development of therapeutic antibodies against proprietary disease specific epitopes identified using Amorfix’s ProMIS discovery technology for treating various oncology indications. Read More

AMRI has extended its commercial supply relationship with GE Healthcare for aminobisamide hydrochloride. Read More

Impact Analytical announced an expansion that includes new testing and analysis laboratories. The project is scheduled to be completed by March 2013. Read More

Kemwell has signed an agreement with Mercury Pharma for the manufacturing of pharmaceuticals at its new production facility in Uppsala, Sweden. Read More

Sartorius Stedim Biotech has launched its Sartoguard NF prefilter series, featuring a combination of high-performance polyethersulfone membranes and nanofleece technology. Read More

People News

AAIPharma has appointed Timothy Rhines as senior director of biopharmaceutical Development. Read More

In addition, AAIPharma has also appointed David Browne director of analytical chemistry. Read More

AmerisourceBergen has named Peyton R. Howell senior vice-president of AmerisourceBergen Corporation, and president of global sourcing and manufacturer relationships. Read More

Pfizer has elected CEO Ian Read as chairman of the board. Read More

Roche has announced several changes to its board of directors, and has proposed CEO Severin Schwan as a new member of the board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here